Sign Up Today and Learn More About Angitia Biopharmaceuticals Stock
Invest in or calculate the value of your shares in Angitia Biopharmaceuticals or other pre-IPO companies through EquityZen's platform.
Angitia Biopharmaceuticals Stock (ANGB)
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.
About Angitia Biopharmaceuticals Stock
Founded
2018
Industries
Software, Artificial Intelligence, Data and Analytics
Angitia Biopharmaceuticals Press Mentions
Stay in the know about the latest news on Angitia Biopharmaceuticals
Postmenopausal Osteoporosis Pipeline Market Landscape Report 2025: The Dawn of Novel Therapies, Emerging Drug Candidates in Focus, Collaborative Efforts and Future Directions
globenewswire • Mar 05, 2025
Angitia Biopharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
globenewswire • Jan 08, 2025
Angitia Biopharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
biospace • Jan 08, 2025
Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases
pulse2 • Dec 17, 2024
Deals in brief: B Capital leads Series A investment in Eureka Robotics, Cove attracts new funding, True Global Ventures backs US-based Prezent, and more
kr-asia • Dec 17, 2024
Join now and verify your accreditation status to gain access to:
- Angitia Biopharmaceuticals Current Valuation
- Angitia Biopharmaceuticals Stock Price
- Angitia Biopharmaceuticals Management
- Available deals in Angitia Biopharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Angitia Biopharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Angitia Biopharmaceuticals Revenue and Financials
- Angitia Biopharmaceuticals Highlights
- Angitia Biopharmaceuticals Business Model
- Angitia Biopharmaceuticals Risk Factors
- Angitia Biopharmaceuticals Research Report from SACRA Research
Trading Angitia Biopharmaceuticals Stock
How to invest in Angitia Biopharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Angitia Biopharmaceuticals through EquityZen funds. These investments are made available by existing Angitia Biopharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Angitia Biopharmaceuticals stock?
Shareholders can sell their Angitia Biopharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
